{"product_id":"emergentbiosolutions-swot-analysis","title":"Emergent BioSolutions SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Strategic Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore a concise SWOT snapshot of Emergent BioSolutions—highlighting resilient product portfolio, regulatory and manufacturing risks, opportunistic vaccine and biodefense demand, and competitive pressures. Want the full, research-backed SWOT with editable Word and Excel deliverables? Purchase the complete report for actionable insights to inform investment, strategy, and pitches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeep biodefense expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDecades of focused work on medical countermeasures—notably as the licensed manufacturer of the FDA‑approved anthrax vaccine BioThrax—have built deep domain knowledge across anthrax, smallpox, chemical and infectious threats. This specialization enables rapid response, scale‑up and regulatory compliance in high‑stakes government and military programs. The expertise cements credibility with agencies like HHS and DoD and differentiates Emergent from generalist biopharma peers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmbedded government relationships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLongstanding ties with BARDA, DoD, HHS and allied governments underpin multi‑year procurement and stockpiling contracts often valued in the hundreds of millions to over $1 billion, providing clear revenue visibility. Repeat awards — government business historically representing roughly 60–80% of sales — confer emergency priority and lower bidding friction. These partnerships guide pipeline alignment with public‑health policy priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified countermeasure portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiversified countermeasure portfolio combining vaccines, antitoxins and specialty biodefense products spreads risk across threat categories and helped Emergent BioSolutions deliver approximately $1.09 billion in 2024 revenue. The breadth supports cross-selling into preparedness budgets—company contracts with U.S. government agencies remain a backbone of sales. Platform reuse enables lifecycle management and buffers single-product volatility, smoothing cash flow across program cycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCDMO capabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eContract development and manufacturing services provide Emergent a capital-efficient growth vector by monetizing excess capacity, stabilizing cash flow through multi-year CDMO engagements and improving asset utilization. CDMO work embeds Emergent in external pipelines, increasing partnership optionality and deal flow, while the service model sharpens operational know-how that transfers to internal biologics programs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCapital‑efficient growth\u003c\/li\u003e\n\u003cli\u003eImproved asset utilization \u0026amp; cash stability\u003c\/li\u003e\n\u003cli\u003ePipeline optionality via external partnerships\u003c\/li\u003e\n\u003cli\u003eOperational know‑how for internal programs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal manufacturing and compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEmergent BioSolutions maintains multiple global manufacturing sites with containment suites and certified quality systems that support complex biologics production and fill-finish services, enabling contracts for the U.S. Strategic National Stockpile. Its regulatory experience across FDA, EMA and other jurisdictions shortens approval and lot-release timelines, while site redundancy enhances supply security for critical stockpiles. This specialized infrastructure and qualification burden create a high barrier to entry for new competitors.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMultiple global sites and containment suites\u003c\/li\u003e\n\u003cli\u003eRegulatory experience across FDA and EMA\u003c\/li\u003e\n\u003cli\u003eRedundancy secures Strategic National Stockpile supply\u003c\/li\u003e\n\u003cli\u003eInfrastructure forms a high barrier to entry\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDecades of biodefense manufacturing expertise enabling rapid scale-up and large government contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDecades of biodefense focus and BioThrax leadership give Emergent deep regulatory and manufacturing expertise for anthrax, smallpox and other countermeasures, enabling rapid scale‑up and emergency responsiveness. Longstanding BARDA\/DoD\/HHS ties drive multi‑year procurement (contract sizes often $100M–$1B+) and historically 60–80% government sales, supporting $1.09B revenue in 2024. Robust CDMO services and multiple containment‑capable sites improve asset utilization and cash stability.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$1.09B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernment sales\u003c\/td\u003e\n\u003ctd\u003e60–80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTypical contract size\u003c\/td\u003e\n\u003ctd\u003e$100M–$1B+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing footprint\u003c\/td\u003e\n\u003ctd\u003eMultiple containment‑capable sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a strategic overview of Emergent BioSolutions’s internal strengths and weaknesses and external opportunities and threats, mapping competitive position, growth drivers, operational gaps, and market risks to inform strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise, Emergent BioSolutions–focused SWOT matrix to quickly identify risks and opportunities, streamlining strategic alignment and executive decision-making for rapid mitigation and growth planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevenue concentration on governments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDependence on U.S. and allied public-sector customers—which account for over 50% of Emergent BioSolutions revenue—creates budget and policy exposure; procurement cycles are lumpy and unpredictable, with multi-quarter gaps common. Delays or rebids can strain cash flows and working capital, while limited private demand for specific countermeasures amplifies concentration risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality and compliance risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiologics manufacturing is complex and prone to deviations that can halt production, as seen in Emergent BioSolutions’ 2021 Baltimore contamination incident that disrupted vaccine manufacturing. Inspection findings or remediation needs have historically raised costs and eroded trust, with regulatory scrutiny continuing into 2024–25. Recovery from such events can take months to years and strain margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct and contract cyclicality\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStockpile replenishments and surge orders are episodic, causing revenue to spike around awarded contracts and dip as lots expire. Revenue can shift with changing threat assessments and timing of federal funding releases, complicating capacity planning and working capital management. Visibility beyond signed options is limited, increasing forecasting risk. Reliance on U.S. government procurement remained central through FY2024–Q1 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeverage and fixed-cost burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLeverage and high fixed costs from capital-intensive facilities and specialized equipment mean underutilization rapidly compresses margins at Emergent BioSolutions, especially when contract volumes fluctuate.\u003c\/p\u003e\n\u003cp\u003eDebt service limits financial flexibility in downturns, forcing prioritization of capex and maintenance over discretionary R\u0026amp;D or BD investments and slowing product pipeline progression.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh fixed-cost base\u003c\/li\u003e\n\u003cli\u003eUnderutilization compresses margins\u003c\/li\u003e\n\u003cli\u003eDebt service constrains flexibility\u003c\/li\u003e\n\u003cli\u003eCapex can crowd out R\u0026amp;D\/BD\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNarrow commercial demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNarrow commercial demand limits Emergent BioSolutions because many biodefense countermeasures lack sustained civilian market pull absent active outbreaks, forcing reliance on government contracts and stockpile purchases. Market education and access are costly for low-incidence threats, restricting routine adoption by hospitals and insurers. Public scrutiny over pricing of biodefense products further constrains pure market-driven growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHeavy dependence on government procurement\u003c\/li\u003e\n\u003cli\u003eHigh costs to educate\/market for rare threats\u003c\/li\u003e\n\u003cli\u003ePricing faces public and payer scrutiny\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic-sector concentration, contamination risk, and fixed-cost squeeze threaten margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConcentration in U.S.\/allied public-sector sales (\u0026gt;50% of revenue) creates procurement and timing risk; private demand for niche countermeasures is limited. Complex biologics manufacturing raises contamination and inspection exposure (Baltimore 2021), with remediation and regulatory scrutiny persisting into 2024–25. High fixed costs and leverage compress margins when contract volumes fall, crowding out discretionary R\u0026amp;D\/BD.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eNote\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic-sector revenue\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNotable incident\u003c\/td\u003e\n\u003ctd\u003eBaltimore contamination, 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory scrutiny\u003c\/td\u003e\n\u003ctd\u003eContinues into 2024–25\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecovery timeline\u003c\/td\u003e\n\u003ctd\u003eMonths–years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eEmergent BioSolutions SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Emergent BioSolutions SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report you'll download, with the same structure, findings, and editable content. Buy now to unlock the complete, detailed file for immediate use in analysis or presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56164289806713,"sku":"emergentbiosolutions-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/emergentbiosolutions-swot-analysis.png?v=1762729949","url":"https:\/\/portersfiveforce.com\/products\/emergentbiosolutions-swot-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}